Brief: Intellia Completes Global Phase 3 HAELO Study Enrollment for Lonvo-Z in Hereditary Angioedema
18/09/2025 12:39
Sept 18 (Reuters) - Intellia Therapeutics Inc NTLA.O: INTELLIA THERAPEUTICS COMPLETES ENROLLMENT IN THE GLOBAL PHASE 3 HAELO STUDY OF LONVOGURAN ZICLUMERAN (LONVO-Z) FOR HEREDITARY ANGIOEDEMA INTELLIA THERAPEUTICS INC - PHASE 3 TOPLINE DATA EXPECTED IN FIRST HALF 2026 INTELLIA THERAPEUTICS INC: ON TRACK TO SUBMIT BLA IN SECOND HALF OF 2026 FOR AN ANTICIPATED U.S. LAUNCH IN FIRST HALF OF 2027 INTELLIA THERAPEUTICS INC: PLAN TO PRESENT ADDITIONAL DATA FROM PHASE 1/2 STUDY IN Q4 OF 2025 Source text: ID:nGNX3Sjsjt Further company coverage: NTLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)